NCT00198250View on ClinicalTrials.gov

Venlafaxine for Hot Flashes After Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Breast Cancer
Interventions
DRUG

venlafaxine

Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

All Listed Sponsors
collaborator

Vanderbilt University

OTHER

lead

Indiana University School of Medicine

OTHER

NCT00198250 - Venlafaxine for Hot Flashes After Breast Cancer | Biotech Hunter | Biotech Hunter